Shares in North Carolina, USA-based vTv Therapeutics (Nasdaq: VTVT) have fallen over a quarter after the firm announced a clinical hold on its diabetes program.
The company is running a Phase III trial of cadisegliatin, an oral, liver-selective glucokinase activator, for people with type 1 diabetes.
The US regulator has stopped work on the CATT1 trial after the detection of a “chromatographic signal” that mass spectrometry could not resolve.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze